374 related articles for article (PubMed ID: 26011489)
1. Challenges in the management of advanced, ER-positive, HER2-negative breast cancer.
Hart CD; Migliaccio I; Malorni L; Guarducci C; Biganzoli L; Di Leo A
Nat Rev Clin Oncol; 2015 Sep; 12(9):541-52. PubMed ID: 26011489
[TBL] [Abstract][Full Text] [Related]
2. Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer.
Reinert T; de Paula B; Shafaee MN; Souza PH; Ellis MJ; Bines J
Chin Clin Oncol; 2018 Jun; 7(3):25. PubMed ID: 30056727
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers.
Nahta R; O'Regan RM
Breast Cancer Res Treat; 2012 Aug; 135(1):39-48. PubMed ID: 22527112
[TBL] [Abstract][Full Text] [Related]
4. Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order.
Perez EA
Drug Resist Updat; 2016 Jan; 24():13-22. PubMed ID: 26830312
[TBL] [Abstract][Full Text] [Related]
5. [Advanced luminal breast cancer (hormone receptor-positive, HER2 negative): New therapeutic options in 2015].
Vanacker H; Bally O; Kassem L; Tredan O; Heudel P; Bachelot T
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S47-52. PubMed ID: 26118876
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy in luminal breast cancers.
Lim E; Winer EP
Breast; 2011 Oct; 20 Suppl 3():S128-31. PubMed ID: 22015279
[TBL] [Abstract][Full Text] [Related]
7. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
Prat A; Baselga J
Nat Clin Pract Oncol; 2008 Sep; 5(9):531-42. PubMed ID: 18607391
[TBL] [Abstract][Full Text] [Related]
8. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
[TBL] [Abstract][Full Text] [Related]
9. First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer.
Peron J; Tredan O; Ray-Coquard I; Bachelot T; Labidi Galy SI; Favier B; Treilleux I; Guastalla JP
Bull Cancer; 2012 Feb; 99(2):E18-25. PubMed ID: 22257781
[TBL] [Abstract][Full Text] [Related]
10. Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer.
Nagaraj G; Ma C
Breast Cancer Res Treat; 2015 Apr; 150(2):231-42. PubMed ID: 25762475
[TBL] [Abstract][Full Text] [Related]
11. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
[TBL] [Abstract][Full Text] [Related]
12. Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient.
Glück S; Arteaga CL; Osborne CK
Clin Cancer Res; 2011 Sep; 17(17):5559-61. PubMed ID: 21764887
[TBL] [Abstract][Full Text] [Related]
13. Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review.
Yeung C; Hilton J; Clemons M; Mazzarello S; Hutton B; Haggar F; Addison CL; Kuchuk I; Zhu X; Gelmon K; Arnaout A
Cancer Metastasis Rev; 2016 Sep; 35(3):427-37. PubMed ID: 27405651
[TBL] [Abstract][Full Text] [Related]
14. Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines.
Matutino A; Joy AA; Brezden-Masley C; Chia S; Verma S
Curr Oncol; 2018 Jun; 25(Suppl 1):S131-S141. PubMed ID: 29910656
[TBL] [Abstract][Full Text] [Related]
15. [Changing behavior of estrogen and progesterone receptors with metastasis or recurrence of breast cancer].
Morimoto K; Koh M; Yamamoto A; Tamura K; Yamamoto K; Yamamoto K; Suehiro S
Gan To Kagaku Ryoho; 2006 Jul; 33(7):925-9. PubMed ID: 16835481
[TBL] [Abstract][Full Text] [Related]
16. Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer.
Başaran GA; Twelves C; Diéras V; Cortés J; Awada A
Cancer Treat Rev; 2018 Feb; 63():144-155. PubMed ID: 29329006
[TBL] [Abstract][Full Text] [Related]
17. Evolution of endocrine adjuvant therapy for early breast cancer.
Lønning PE
Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S19-30. PubMed ID: 20374026
[TBL] [Abstract][Full Text] [Related]
18. Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.
Dalmau E; Armengol-Alonso A; Muñoz M; Seguí-Palmer MÁ
Breast; 2014 Dec; 23(6):710-20. PubMed ID: 25311296
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer.
Fedele P; Orlando L; Schiavone P; Calvani N; Caliolo C; Quaranta A; Nacci A; Cinieri S
Crit Rev Oncol Hematol; 2015 Jun; 94(3):291-301. PubMed ID: 25624176
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]